Pierre R. Band

TL;DR: The prognostic effect of weight loss prior to chemotherapy was analyzed using data from 3,047 patients enrolled in 12 chemotherapy protocols of the Eastern Cooperative Oncology Group and increased with increasing number of anatomic sites involved with metastases, but within categories of Anatomic involvement, weight loss was associated with decreased median survival.

TL;DR: L-PAM has been demonstrated to be effective in the treatment of women with primary breast cancer, particularly those who are premenopausal, with minimal undesirable side effects.

TL;DR: A shift of the survival curves suggests a delay in the time of tumor regrowth consistent with the ability of metronidazole to make the hypoxic tumor cells less radioresistant.

TL;DR: The superior antitumor effect of CMF over L‐PAM suggests that it may be a more effective drug regimen to be used as an adjuvant to primary therapy.

TL;DR: Results strongly suggest that CMF(P) and AV are clinically noncross‐resistant regimens, that AV and CMF are essentially equivalently active induction regimen, and that CMFP is superior to CMF and AV.